A drug shortage is a quality failure with a body count.
Live FDA drug shortage data (openFDA), grouped by status, availability, and therapeutic area. The FDA’s own root-cause analysis puts manufacturing and quality problems at the centre of the shortage crisis — which is why SPEQ treats the shortage list as a quality-system signal, not just a supply-chain one.
By initial FDA posting date. openFDA lists active shortages, so older cohorts thin as entries resolve.
The FDA’s 2019 report Drug Shortages: Root Causes and Potential Solutions found the dominant drivers are not scarcity of raw materials but a lack of incentives to produce, and manufacturing/quality problems that force production to stop. Mature quality systems — the difference a QMM assessment measures — are what keep a line running.
| Drug | Company | Therapeutic area | Availability | Status | Posted |
|---|---|---|---|---|---|
| Lidocaine Hydrochloride InjectionInjection | Hospira, Inc., a Pfizer Company | Anesthesia | — | To Be Discontinued | 2025-11-07 |
| Calcium Chloride InjectionInjection | Hospira, Inc., a Pfizer Company | Cardiovascular | — | To Be Discontinued | 2025-11-07 |
| Sodium Bicarbonate InjectionInjection | Hospira, Inc., a Pfizer Company | Endocrinology/Metabolism | — | To Be Discontinued | 2025-11-07 |
| Atropine Sulfate InjectionInjection | Hospira, Inc., a Pfizer Company | Anesthesia | — | To Be Discontinued | 2025-11-07 |
| Ketamine Hydrochloride InjectionInjection | Pfizer Inc. | Anesthesia | — | To Be Discontinued | 2025-11-07 |
| Atropine Sulfate InjectionInjection | Hospira, Inc., a Pfizer Company | Anesthesia | — | To Be Discontinued | 2025-11-07 |
| Epinephrine InjectionInjection | Hospira, Inc., a Pfizer Company | Cardiovascular | — | To Be Discontinued | 2025-11-07 |
| Sodium Bicarbonate InjectionInjection | Hospira, Inc., a Pfizer Company | Endocrinology/Metabolism | — | To Be Discontinued | 2025-11-07 |
| Lidocaine Hydrochloride InjectionInjection | Hospira, Inc., a Pfizer Company | Analgesia/Addiction | — | To Be Discontinued | 2025-11-07 |
| Epinephrine InjectionInjection | Hospira, Inc., a Pfizer Company | Cardiovascular | — | To Be Discontinued | 2025-11-07 |
| Dextrose Monohydrate 50% InjectionInjection | Hospira, Inc., a Pfizer Company | Endocrinology/Metabolism | — | To Be Discontinued | 2025-11-07 |
| Lasmiditan Succinate TabletTablet | Eli Lilly and Co. | Neurology | — | To Be Discontinued | 2025-11-03 |
| Lasmiditan Succinate TabletTablet | Eli Lilly and Co. | Neurology | — | To Be Discontinued | 2025-11-03 |
| Atazanavir Sulfate; Cobicistat TabletTablet | Bristol Myers Squibb Co. | Antiviral | — | To Be Discontinued | 2025-11-03 |
| Everolimus TabletTablet | Mylan Pharmaceuticals Inc., a Viatris Company | Transplant | — | To Be Discontinued | 2025-11-03 |
| Acetaminophen; Oxycodone Hydrochloride TabletTablet | Endo Pharmaceuticals, Inc. | Analgesia/Addiction | — | To Be Discontinued | 2025-11-03 |
| Everolimus TabletTablet | Mylan Pharmaceuticals Inc., a Viatris Company | Transplant | — | To Be Discontinued | 2025-11-03 |
| Lasmiditan Succinate TabletTablet | Eli Lilly and Co. | Neurology | — | To Be Discontinued | 2025-11-03 |
| Lasmiditan Succinate TabletTablet | Eli Lilly and Co. | Neurology | — | To Be Discontinued | 2025-11-03 |
| Lasmiditan Succinate TabletTablet | Eli Lilly and Co. | Neurology | — | To Be Discontinued | 2025-11-03 |
| Scopolamine Transdermal SystemTransdermal System | Padagis US LLC | Gastroenterology | — | To Be Discontinued | 2025-11-03 |
| Everolimus TabletTablet | Mylan Pharmaceuticals Inc., a Viatris Company | Transplant | — | To Be Discontinued | 2025-11-03 |
| Lasmiditan Succinate TabletTablet | Eli Lilly and Co. | Neurology | — | To Be Discontinued | 2025-11-03 |
| Phenobarbital TabletTablet | Endo Pharmaceuticals, Inc. | Analgesia/Addiction | — | To Be Discontinued | 2025-10-31 |
| Phenobarbital TabletTablet | Endo Pharmaceuticals, Inc. | Analgesia/Addiction | — | To Be Discontinued | 2025-10-31 |
Data: U.S. FDA openFDA drug/shortages API, which lists activeshortages (Current or To Be Discontinued) — it carries no per-record cause field, so SPEQ makes no root-cause claim on individual drugs; the quality framing above is cited FDA context. openFDA publishes shortage data for drugs only; SPEQ’s cross-industry coverage lives in the recall Explorer(drug, device & food).